We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Vir Biotechnology Inc (VIR) NPV

Sell:$38.35 Buy:$38.39 Change: $5.92 (13.36%)
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
Sell:$38.35
Buy:$38.39
Change: $5.92 (13.36%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
Sell:$38.35
Buy:$38.39
Change: $5.92 (13.36%)
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on treating and preventing serious infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. Its development pipeline consists of product candidates targeting the coronavirus disease 2019 (COVID-19), hepatitis B virus (HBV), influenza A virus and human immunodeficiency virus (HIV). Its product candidates include VIR-7831 and VIR-7832, VIR-2218, VIR-3434, VIR-2482 and VIR-111. The Company is developing VIR-7831 and VIR-7832 for the treatment of COVID-19 infection, which are severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing monoclonal antibody (mAbs). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb.VIR-1111 is a subcutaneously administered HIV T cell vaccine.

Contact details

Address:
499 Illinois St Ste 500
SAN FRANCISCO
94158-2521
United States
Telephone:
+1 (415) 9064324
Website:
https://www.vir.bio/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VIR
ISIN:
US92764N1028
Market cap:
$5.80 billion
Shares in issue:
130.83 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • George Scangos
    President, Chief Executive Officer, Director
  • Howard Horn
    Chief Financial Officer, Secretary
  • Herbert Virgin
    Executive Vice President of Research and Chief Scientific Officer
  • Ann Hanly
    Chief Technology Officer
  • Steven Rice
    Chief Administrative Officer
  • Phil Pang
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.